NHS England is accelerating access to pioneering mRNA cancer vaccines in patients with advanced head and neck cancer, offering new hope for one of the most challenging forms of illness.
In England, more than 100 people living with advanced head and neck cancer will be quickly followed up in clinical trials for Progress (BNT113-01) over the next year.
The study is being conducted at 15 NHS hospitals and is coordinated by the Southampton Clinical Trials Force.
The initiative is supported by the NHS Cancer Vaccine Launch Pad (CVLP), a national “matchmaking” program that connects eligible patients to take cutting-edge vaccine and immunotherapy trials.
This is the third cancer vaccine trial to be carried out via CVLP, which has already referred 550 patients to intestinal and skin cancer studies.
The first participants have already received the investigation vaccine and will be registered with the nearest participating hospital.
Professor Peter Johnson, clinical director of NHS England Cancer, highlighted the importance of the trial. “As more patients with advanced head and neck cancer, we will have access to this potentially transformative vaccine, offering new hope to keep the disease at bay.
“The NHS is constantly looking for evidence-backed treatment innovations to improve the survival and quality of life of people diagnosed with cancer. This expansion of CVLP gives hundreds of patients the opportunity to become part of cutting-edge advances in cancer treatment.”
Why Head and Neck Cancer Need a New Solution
Over 11,000 people in the UK are diagnosed with head and neck cancer each year, which can occur in the mouth, throat, or voice box.
Advances in treatment have improved early stage outcomes, but progressive disease is notoriously difficult to treat.
The recurrence rate is high, survival rates are calm, and fewer than half of the patients are alive after more than two years of diagnosis.
By targeting the underlying virus causes of cancer, researchers hope that the vaccine can promote survival and reduce recurrence rates in patients with limited treatment options.
Use mRNA to fight cancer
The research treatment developed by Life Sciences Company BionTech uses the same mRNA technology that supported several Covid-19 vaccines, but the targets are very different.
It is designed to train the immune system to recognize and destroy cancer cells containing proteins associated with human papillomavirus type 16 (HPV-16).
This strain is responsible for approximately 95% of HPV-related squamous cell carcinoma of the head and neck. Vaccines encode two specific proteins frequently found in these tumors, helping the body’s defenses identify cancer cells as threats and attack them.
The Minister of Science, Balance highlighted the transformational potential of vaccines. “Advances in cancer research hope that patients will improve their quality of life and increase their chances of survival.
“This clinical trial is an important milestone in an exciting new approach for head and neck cancer patients.
“The partnership with BionTech is being offered for patients across the country. We hope to see such ambitious work as we continue to invest in research and development and AI as part of our £1 billion support to the UK over the next decade.
“We are determined to work closely with leading life science companies like BionTech to drive this thriving sector to even higher heights as part of our modern industrial strategy.”
Speeding up cancer research
CVLP is a joint effort by the NHS England, the UK government and BionTech.
It has helped to reduce delays in exam registration, and some studies began nearly a year before expectations.
The long-term goal of the program is to match thousands of patients with innovative cancer vaccines and immunotherapy trials covering a wide range of tumor types.
For those facing advanced head and neck cancer, the trial offers more than just a new treatment option. This represents a potential turning point in how these aggressive cancers are fought.
Source link
